BR100 Increased By (0.36%)
BR30 Decreased By (-0.13%)
KSE100 Increased By (0.22%)
KSE30 Increased By (0.37%)
AGHA 6.68 Increased By ▲ 0.01 (0.15%)
BECO 4.37 No Change ▼ 0.00 (0%)
BML 57.32 Increased By ▲ 0.88 (1.56%)
BOP 30.35 Increased By ▲ 0.01 (0.03%)
CNERGY 13.12 Increased By ▲ 0.03 (0.23%)
CSIL 5.41 Increased By ▲ 0.05 (0.93%)
FCCL 52.79 Increased By ▲ 0.41 (0.78%)
FFL 14.72 Decreased By ▼ -0.02 (-0.14%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.09 No Change ▼ 0.00 (0%)
KOSM 5.73 Increased By ▲ 0.77 (15.52%)
LOTCHEM 26.46 Decreased By ▼ -0.89 (-3.25%)
MLCF 93.16 Increased By ▲ 0.41 (0.44%)
NBP 164.66 Decreased By ▼ -0.32 (-0.19%)
NCPL 55.66 Increased By ▲ 0.02 (0.04%)
NPL 61.16 Decreased By ▼ -0.10 (-0.16%)
OGDC 316.73 Decreased By ▼ -1.03 (-0.32%)
PACE 9.87 Decreased By ▼ -0.06 (-0.6%)
PAEL 35.63 Increased By ▲ 0.13 (0.37%)
PIBTL 14.68 Increased By ▲ 0.11 (0.75%)
PPL 226.91 Decreased By ▼ -0.88 (-0.39%)
PRL 93.02 Increased By ▲ 0.45 (0.49%)
PTC 60.26 Decreased By ▼ -0.37 (-0.61%)
SSGC 23.81 Increased By ▲ 0.01 (0.04%)
TBL 8.75 Increased By ▲ 0.07 (0.81%)
TELE 7.80 Increased By ▲ 0.02 (0.26%)
TPL 22.35 Increased By ▲ 0.12 (0.54%)
TPLP 12.97 Increased By ▲ 0.30 (2.37%)
TREET 22.16 Decreased By ▼ -0.38 (-1.69%)
TRG 56.56 Decreased By ▼ -1.24 (-2.15%)

The Drug Regulatory Authority of Pakistan (DRAP)’s first drug testing laboratory has secured prequalification from the World Health Organization (WHO) amid efforts of the Special Investment Facilitation Council (SIFC), reflecting growing global confidence in Pakistan’s regulatory systems.

According to a statement on Thursday, SIFC ensured coordination at the domestic level while also engaging effectively with international stakeholders to make this achievement possible.

The state-of-the-art drug testing laboratory will be established in Karachi and will operate under the administration of DRAP.

DRAP urged to follow full process before declaring medicines substandard

As per the statement, multiple domestic and international challenges were successfully addressed throughout the process by SIFC’s.

The WHO accreditation is expected to significantly enhance the global credibility of Pakistan’s pharmaceutical quality and regulatory framework, leading to a notable increase in pharmaceutical exports. It will also strengthen investor confidence in Pakistan’s pharmaceutical manufacturing sector.

Furthermore, this development will reduce Pakistan’s reliance on foreign laboratories by enabling high-quality testing capabilities within the country.

The council was of the view that this achievement underscores Pakistan’s continued progress towards regulatory modernisation and institutional strengthening, with SIFC playing a pivotal role in advancing these efforts.

Comments

200 characters remaining